Stay updated on CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial

Sign up to get notified when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T14:23:02.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version of the study protocol for the APX005M clinical trial, with significant changes in the study design and structure, including the removal of detailed descriptions of the Phase 1-2 study and the addition of a more concise overview of the Phase 1b and Phase 2 components.
    Difference
    20%
    Check dated 2025-04-16T10:33:47.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T04:55:41.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T22:15:47.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T19:14:06.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    1%
    Check dated 2025-02-10T09:21:52.000Z thumbnail image

Stay in the know with updates to CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.